Literature DB >> 25797538

Personalizing surgical margins in retroperitoneal sarcomas.

Dario Callegaro1, Marco Fiore, Alessandro Gronchi.   

Abstract

Retroperitoneal sarcomas are a group of diseases that behave differently from one another. Well-differentiated liposarcomas have an indolent biology but show a tendency to recur locally even years after primary resection. Dedifferentiated liposarcomas are characterized by a very high local recurrence risk, while the metastatic risk mainly depends on the histological characteristics of the dedifferentiated component. In leiomyosarcomas, hematogenous spread informs prognosis while local recurrences are far less common. Surgery is the cornerstone of treatment of all retroperitoneal sarcoma subtypes and its quality is the only treatment-related factor able to improve the oncological outcome. A frontline extended surgical approach is all the more critical in subtypes in which local control directly impacts prognosis.

Entities:  

Keywords:  leiomyosarcoma; liposarcoma; outcome; prognosis; retroperitoneal sarcoma; sarcoma; solitary fibrous tumor; surgery; surgical margins

Mesh:

Year:  2015        PMID: 25797538     DOI: 10.1586/14737140.2015.1028375

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  10 in total

1.  Paraneoplastic Syndrome Associated with the Retroperitoneal Dedifferentiated Liposarcoma: an Atypical Presentation and Review of the Literature.

Authors:  Jeewan Ram Vishnoi; Ankit Jain; Sanjeev Misra; Puneet Pareek; Meenakshi Rao; Binit Sureka; Ashok Puranik
Journal:  Indian J Surg Oncol       Date:  2019-08-13

2.  A Prospective Observational Study of Multivisceral Resection for Retroperitoneal Sarcoma: Clinical and Patient-Reported Outcomes 1 Year After Surgery.

Authors:  Marco Fiore; Cinzia Brunelli; Rosalba Miceli; Michele Manara; Susanna Lenna; Nicolò N Rampello; Dario Callegaro; Chiara Colombo; Stefano Radaelli; Sandro Pasquali; Augusto T Caraceni; Alessandro Gronchi
Journal:  Ann Surg Oncol       Date:  2020-11-11       Impact factor: 5.344

Review 3.  [Retroperitoneal tumors].

Authors:  O Schmalz
Journal:  Urologe A       Date:  2016-06       Impact factor: 0.639

4.  Prophylactic Ureteral Catheter Placement Appears to Reduce Intraoperative Ureteric Injury During Resection of Primary Retroperitoneal Liposarcoma.

Authors:  Xiaobing Chen; Jun Chen; Ferdinando Carlo Maria Cananzi; Wenjie Li; Vittorio Quagliuolo; Chenghua Luo; Yinmo Yang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 5.  Recent advances in the management of liposarcoma.

Authors:  Nadar A Nassif; William Tseng; Camille Borges; Peter Chen; Burton Eisenberg
Journal:  F1000Res       Date:  2016-12-22

6.  Different quality of treatment in retroperitoneal sarcomas (RPS) according to hospital-case volume and surgeon-case volume: a retrospective regional analysis in Italy.

Authors:  Sergio Sandrucci; Agostino Ponzetti; Claudio Gianotti; Baudolino Mussa; Patrizia Lista; Giovanni Grignani; Marinella Mistrangelo; Oscar Bertetto; Daniela Di Cuonzo; Giovannino Ciccone
Journal:  Clin Sarcoma Res       Date:  2018-02-28

Review 7.  Retroperitoneal Sarcoma Care in 2021.

Authors:  Erika Schmitz; Carolyn Nessim
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639

8.  A systematic review of margin status in retroperitoneal liposarcomas: Does the R0 margin matter?

Authors:  Benjamin Paik; Chin Jin Seo; Joey Wee-Shan Tan; Wen Kai Darryl Juan; Khee Chee Soo; Chin-Ann Johnny Ong; Claramae Shulyn Chia; Jolene Si Min Wong
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

Review 9.  Surgical Principles of Primary Retroperitoneal Sarcoma in the Era of Personalized Treatment: A Review of the Frontline Extended Surgery.

Authors:  Paula Munoz; Pedro Bretcha-Boix; Vicente Artigas; José Manuel Asencio
Journal:  Cancers (Basel)       Date:  2022-08-24       Impact factor: 6.575

10.  Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma.

Authors:  Michael J Nathenson; Constance M Barysauskas; Robert A Nathenson; William F Regine; Nader Hanna; Edward Sausville
Journal:  World J Surg Oncol       Date:  2018-10-11       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.